ClinicalTrials.gg
RecruitingNCT04649398Updated Oct 19, 2023

Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration

An observational study in Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia and Vasospasm, Cerebral, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by Medical University of Vienna · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Subarachnoid Hemorrhage with a site in Austria — 3 open to participants now, 3 under way, none of them phase 3. Subarachnoid Hemorrhage · Austria.

Started
2020
with 4 others
Observational
4 of 14
2 open now
Registered
12th of 14
by date
Lead sponsor
2 of 14
Medical University of Vienna

Among the 14 studies in Subarachnoid Hemorrhage with a site in Austria, this one is one of 5 that started in 2020, is one of 4 observational ones, and was the 12th registered.

Subarachnoid Hemorrhage

513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.

Browse Subarachnoid Hemorrhage studies →

Open to participants now

3 of the 14 studies in Subarachnoid Hemorrhage with a site in Austria are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Subarachnoid Hemorrhage with a site in Austria, or all of them as a file.
02

Study summary

Nimodipine reduces the risk of poor outcome and delayed cerebral ischemia in patients suffering aneurysmal subarachnoid haemorrhage (SAH), but its mode of action is unknown. Its beneficial effect is assumed to be due its neuroprotective effects by reducing intracellular calcium and thereby cellular apoptosis, but higher concentrations might induce marked systemic hypotension, thereby inducing cerebral ischemia. Since several dosing regimes and routes of administration with inconclusive superiority exist and since the target site concentration of nimodipine - the unbound drug concentrations beyond the blood-brain barrier - is still not known, it is reasonable to measure nimodipine concentrations within the blood, cerebrospinal fluid (CSF) and interstitial brain tissue following oral, intra-venous and intra-arterial administration and correlate intra-arterial nimodipine administration to measures of cerebral metabolism and oxygenation.

Therefore, the investigators propose to investigate in 30 patients suffering severe aneurysmal SAH and requiring cerebral microdialysis for cerebral neurochemical monitoring:

  • the ability of nimodipine to penetrate into the brain of neurointensive care patients by comparing exposure in brain, CSF and plasma, dependent on the route of administration (i.e. oral, intra-venous, and intra-arterial) and dosing intra-venously (0.5 - 2mg/h)
  • the impact of orally, intra-venously, and intra-arterially delivered nimodipine on cerebral metabolism, i.e. lactate/pyruvate ratio, pbtO2 and transcranial doppler flow velocities
  • the effect of oral and intra-venous nimodipine on systemic hemodynamic and cardiac parameters, using continuous Pulse Contour Cardiac Output (PiCCO) monitoring
  • the penetration properties of ethanol - as an excipient of nimodipine infusion - into the brain by comparing exposure in brain, CSF and plasma and quantifying the neuronal exposure to alcohol dependent on blood levels
03

Conditions studied

  • Subarachnoid Hemorrhage, Aneurysmal
  • Delayed Cerebral Ischemia
  • Vasospasm, Cerebral
04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients requiring intensive care and bedside cerebral microdialysis for cerebral neurochemical monitoring as standard care with a clinical indication for concomitant treatment with either oral, intra-venous or intra-arterial nimodipin

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patient age > 18 years
  • aneurysmal subarachnoid hemorrhage
  • sedated and mechanically ventilated
  • application of brain microdialysis as standard care (due to the severity of subarachnoid haemorrhage or secondary deterioration)
  • oral, intra-venous or intra-arterial administration of nimodipine due to clinical indication

Exclusion criteria

Exclusion Criteria:

  • for nimodipine
  • no need of intensive care and bedside cerebral microdialysis as standard care
  • any disease considered relevant for proper performance of the study or risks to the patient, at the discretion of the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • oral nimodipine

    60mg of nimodipine is orally administered every 4 h,

    Drug: Nimodipine

  • intra-venous nimodipine

    nimodipine is continuously administered intra-venously, starting with 0.5 mg/h on day 1 and increased every day for 0.5 mg/h to a maximum dose of 2.0mg/h on day 4

    Drug: Nimodipine

  • intra-arterial nimodipine

    during endovascular procedure 2mg of nimodipine is infused via a microcatheter into the internal carotid artery for 20 minutes

    Drug: Nimodipine

Interventions

  • If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.

06

What researchers measure

Primary outcomes

  1. cerebral nimodipine concentrations

    Area under the concentration-time curve in brain, cerebrospinal fluid and serum, dependent on the route of administration (i.e. oral, intra-venous, and intra-arterial)

    Time frame: during the intervention

  2. cerebral ethanol concentrations

    Area under the concentration-time curve and maximum concentrations in brain tissue, CSF and blood after intravenous administration

    Time frame: during the intervention

Secondary outcomes

  1. cerebral lactate/pyruvate ratio (LPR)

    determined by cerebral microdialysis

    Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration

  2. brain tissue oxygen tension (pbtO2)

    determined by cerebral parenchymal probes

    Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration

  3. cardiac output

    measured by Pulse Contour Cardiac Output (PiCCO) monitoring

    Time frame: during the intervention

  4. fluid responsiveness

    measured by Pulse Contour Cardiac Output (PiCCO) monitoring

    Time frame: during the intervention

  5. extravascular lung water index

    measured by Pulse Contour Cardiac Output (PiCCO) monitoring

    Time frame: during the intervention

  6. systemic vascular resistance index

    measured by Pulse Contour Cardiac Output (PiCCO) monitoring

    Time frame: during the intervention

  7. transcranial doppler flow velocities

    measured in the middle cerebral artery ipsilateral to the microdialysis probe

    Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration

  8. angiographic vasospasm

    mild: vessel diameter from 60-99%, moderate: vessel diameter from 30-59%, severe: vessel diameter \<30% of the physiological lumen

    Time frame: immediately after the intervention

  9. cerebral perfusion pressure

    measured continuously via intra-arterial and intracranial probes

    Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration

  10. incidence of delayed ischemic strokes

    ischemic strokes on CT scans

    Time frame: 3-21 days following subarachnoid haemorrhage

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Jul 2024, 44 months after the start.

Of 117 non-industry observational studies under Subarachnoid Hemorrhage, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 127. This study's planned 44 months is close to that.

Counting every sponsor, half of 120 studies reached it within 40 months; a quarter within 19 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2020
First posted
Dec 2, 2020
StartActual
Nov 25, 2020
Primary completionEst.
Jul 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Oct 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04649398
Collaborators
University of Vienna, Austrian Science Fund (FWF)
Responsible party
Arthur Hosmann (Principal Investigator, Medical University of Vienna) — Principal investigator
First posted
Dec 2, 2020
Start date
Nov 25, 2020
Primary completion
Jul 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Oct 19, 2023

Study contacts

Arthur Hosmann, MD PhD
Contact
arthur.hosmann@meduniwien.ac.at
+43/1/40400 ext. 25650

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion